Follow @newyorkercartoons on Instagram and sign up for the Daily Humor newsletter for more funny stuff. Palestinians ...

Artists take on self-evident truths, recent history, and more A free daily email with the biggest news stories of the day – and the best features from TheWeek.com Contact me with news and offers ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Your trusted source for the latest news delivered weekdays from the team at U.S. News and World Report. Sign in to manage your newsletters » Sign up to receive the latest updates from U.S News ...

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox. From our morning news briefing to a weekly Good News Newsletter, get the ...

Denmark is home to Novo Nordisk (NYSE:NVO), the company behind Ozempic and Wegovy, two of the most in-demand drugs in the U.S. for weight loss and diabetes treatment. With demand for those drugs ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Wegovy sales soared 107% at constant exchange rates to DKK19.87 billion, just below estimates. Ozempic sales rose 12% to DKK33.85 billion, above expectations. Novo Nordisk Sees 2025 Sales Growth ...

Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk predicted growth will slow this year. The Danish pharmaceutical company has ...